Physician profile
Robert C Maynard
NPI 1952525917
$5,401.66
in general payments reported to CMS, 2019-2025
36 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $862 · 2020: $179 · 2021: $475 · 2022: $771 · 2023: $728 · 2024: $1,257 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,114.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,137.87 | 2019-2025 | Amplatzer Amulet, Ensite Precision, Aveir |
| Novartis Pharmaceuticals Corporation | $399.95 | 2019-2025 | |
| Amgen INC. | $371.07 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $314.80 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $310.47 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.28 | 2019-2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $195.53 | 2023-2024 | Inpefa |
| Impulse Dynamics (USA) INC. | $167.13 | 2022-2024 | Optimizer |
| Pfizer INC. | $115.17 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $113.95 | 2020-2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $103.39 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $92.72 | 2020-2024 | Wainua |
| E.R. Squibb & Sons, L.L.C. | $76.64 | 2019-2025 | Camzyos |
| United Therapeutics Corporation | $63.21 | 2024-2025 | Tyvaso, Tyvaso |
| Boston Scientific Corporation | $57.24 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $55.64 | 2020-2024 | Sapien 3 Ultra Resilia |
| Kowa Pharmaceuticals America, INC. | $55.04 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $51.37 | 2019-2023 | |
| Ekos Corporation | $40.00 | 2019 | |
| Heartflow, INC. | $36.51 | 2023 | Ffrct |
| Cardiva Medical, INC. | $35.91 | 2023 | Cardiva Vascade 6/7f Vcs |
| Kiniksa Pharmaceuticals, LTD. | $34.54 | 2023 | Arcalyst |
| Terumo Medical Corporation | $33.27 | 2024 | Angio-Seal |
| Esperion Therapeutics, INC. | $32.17 | 2022-2023 | Nexletol |
| Baxter Healthcare | $30.16 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Kestra Medical Technology Services, INC. | $29.23 | 2025 | Assure Wcd |
| Csl Behring | $23.73 | 2019 | |
| Shockwave Medical, INC | $23.35 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.09 | 2025 | Amvuttra |
| Regeneron Healthcare Solutions, INC. | $20.28 | 2021 | |
| Chiesi USA, INC. | $20.17 | 2022 | |
| Bridgebio Pharma, INC. | $19.93 | 2025 | Attruby |
| Braemar Manufacturing, LLC | $19.77 | 2019 | |
| Lundbeck LLC | $17.19 | 2019 | |
| Medtronic, INC. | $17.03 | 2025 | V-Loc 180 |
| Genzyme Corporation | $16.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Maynard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.